Esophageal Cancer
1,040
197
245
443
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
124 trials with published results (12%)
Research Maturity
443 completed trials (43% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.6%
89 terminated out of 1040 trials
83.3%
-3.3% vs benchmark
8%
83 trials in Phase 3/4
28%
124 of 443 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 443 completed trials
Clinical Trials (1040)
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
AI-Driven Digital Twin and Drug Simulation for Esophageal Cancer
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Esophageal Cancer in Northeastern Iran
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
IDOV-Immune for Advanced Solid Tumors
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
AB122 Platform Study
Multimodal Al for Precision Diagnosis of Esophageal Cancer
Distance-Based Exercise to Preserve Function and Prevent Disability
INEC Study: Immuno-modulating Enteral Nutrition in Cancer
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
Esophageal Cancer Genetics Studies